{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:08:39Z","timestamp":1773835719131,"version":"3.50.1"},"reference-count":23,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"1","license":[{"start":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T00:00:00Z","timestamp":1527638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Commun"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      Patients with relapsed\/refractory B\u2010cell lymphomas have limited treatment options. GERSHWIN is an open\u2010label, single\u2010arm, phase Ib study of obinutuzumab monotherapy in Chinese patients with histologically documented CD20\n                      <jats:sup>+<\/jats:sup>\n                      relapsed\/refractory chronic lymphocytic leukemia (CLL), diffuse large B\u2010cell lymphoma (DLBCL), or follicular lymphoma (FL). The primary outcome measure of pharmacokinetics has been previously reported. We now present data on the secondary endpoint measures (e.g., safety, and efficacy and pharmacodynamics).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p xml:lang=\"en\">Patients received 1000 mg obinutuzumab intravenously on days 1, 8, and 15 of cycle 1 (CLL patients; first dose split over 2 days), and on day 1 of cycles 2\u20138. Each cycle lasted for 21 days; the treatment period was 24 weeks. All subjects receiving at least one dose of obinutuzumab were included in the analysis of safety, efficacy, as well as pharmacodynamics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      A total of 48 patients (&gt; 18 years of age) were enrolled (CLL: 12; DLBCL: 23; FL: 13). The subjects received a median of two lines of anticancer treatment prior to the enrollment. Thirty\u2010five patients (72.9%) had at least one adverse event (AE). The most frequent AE was infusion\u2010related reactions (15 patients; 31.3%), followed by pyrexia (11 patients; 22.9%). Treatment\u2010related AEs were reported in 28 patients (58.3%), and included one death (interstitial lung disease). End\u2010of\u2010treatment (EoT) response rate was 33.3%. Best overall response rate was 47.9%. Most CLL patients achieved a partial response at EoT (58.3%). CD19\n                      <jats:sup>+<\/jats:sup>\n                      depletion occurred in 75.0% of the patients with CLL, and all patients with FL and DLBCL.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p xml:lang=\"en\">The safety and efficacy of obinutuzumab monotherapy in Chinese patients with B\u2010cell lymphomas were similar to that observed in previous studies in non\u2010Chinese patients; no new safety signals were observed.<\/jats:p>\n                    <jats:p xml:lang=\"en\">\n                      <jats:italic toggle=\"yes\">Clinical trial registration ID<\/jats:italic>\n                      NCT01680991\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40880-018-0300-5","type":"journal-article","created":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T21:45:51Z","timestamp":1527630351000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety and efficacy of obinutuzumab in Chinese patients with B\u2010cell lymphomas: a secondary analysis of the GERSHWIN trial"],"prefix":"10.34133","volume":"38","author":[{"given":"Yan","family":"Qin","sequence":"first","affiliation":[{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, P. R. China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[{"name":"Peking University","place":["Beijing, P. R. China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhixiang","family":"Shen","sequence":"additional","affiliation":[{"name":"Shanghai Jiaotong University","place":["Shanghai, P. R. China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[{"name":"Guangdong General Hospital\/Guangdong Academy of Medical Sciences","place":["Guangzhou, P. R. China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Ji","sequence":"additional","affiliation":[{"name":"Shanghai Roche Pharmaceuticals Ltd","place":["Shanghai, P. R. China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanling","family":"Hsu","sequence":"additional","affiliation":[{"name":"Roche (China) Holding Ltd","place":["Shanghai, P. R. China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Peking University","place":["Beijing, P. R. China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuankai","family":"Shi","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, P. R. China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"221","published-online":{"date-parts":[[2018,5,30]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.827785"},{"issue":"2","key":"e_1_3_2_3_2","first-page":"111","article-title":"Distribution pattern of lymphoma subtypes in China: a nationwide multicenter study of 10002 cases","volume":"11","author":"Li XQ","year":"2012","unstructured":"Li XQ, Li GD, Gao ZF, Zhou XG, Zhu XZ. Distribution pattern of lymphoma subtypes in China: a nationwide multicenter study of 10002 cases. J Diagn Concepts Pract. 2012; 11 (2): 111\u2013115.","journal-title":"J Diagn Concepts Pract"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0708875"},{"issue":"6","key":"e_1_3_2_5_2","first-page":"1927","article-title":"Rituximab (anti\u2010CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier B","year":"1998","unstructured":"Coiffier B, Haioun C, Ketterer N, Engert AA, Tilly H, Ma D, et al. Rituximab (anti\u2010CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998; 92 (6): 1927\u20131932.","journal-title":"Blood"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.09.027"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.2165\/11201110\u2010000000000\u201000000"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.152272"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102014\u201007\u2010586610"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.9585"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.9718"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.14"},{"key":"e_1_3_2_15_2","unstructured":"GAZYVA prescribing information . http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm\/index.cfm?fuseaction=Search.DrugDetails. Accessed 1 July 2016."},{"key":"e_1_3_2_16_2","unstructured":"GAZYVARO summary of product characteristics . http:\/\/www.medicines.org.uk\/emc. Accessed 1 July 2016."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2139"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(16)30097\u20103"},{"key":"e_1_3_2_19_2","unstructured":"Zhai J Qin Y Zhu J Song Y Shen Z Du X et al. Pharmacokinetics of obinutuzumab in Chinese patients with B\u2010cell lymphomas. Br J Clin Pharmacol. 2017546533810.1111\/bcp.13232"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102007\u201006\u2010093906"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2015.07.003"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.41"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12040"}],"container-title":["Cancer Communications"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40880-018-0300-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40880-018-0300-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1186%2Fs40880-018-0300-5","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40880-018-0300-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.1186\/s40880-018-0300-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:56:42Z","timestamp":1773824202000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.1186\/s40880-018-0300-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,30]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1186\/s40880-018-0300-5"],"URL":"https:\/\/doi.org\/10.1186\/s40880-018-0300-5","relation":{},"ISSN":["2523-3548"],"issn-type":[{"value":"2523-3548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,30]]},"assertion":[{"value":"2017-10-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"31"}}